FEATURED COMPANIES
- AstraZeneca Plc
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. Hoffmann-La Roche Ltd
- Gamma Vaccines Pty Ltd
The global influenza vaccine market was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.
Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.
The key factors that drive the growth of the global influenza vaccine market include an increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upa surge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.
The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Vaccine type
North America
Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.
The key factors that drive the growth of the global influenza vaccine market include an increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upa surge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.
The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global influenza vaccine market is provided.
- An extensive analysis of various regions provides insights that allows companies to strategically plan their business moves.
By Vaccine type
- Quadrivalent
- Trivalent
- Seasonal
- Pandemic
- Egg-based
- Cell-based
- Pediatric
- Adult
- Injection
- Nasal Spray
North America
- U.S.
- Canada
- Mexico
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- AstraZeneca Plc.
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. HoffmannoLa Roche Ltd.
- Gamma Vaccines Pty Ltd.
- GlaxoSmithKline Plc.
- Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
- Novartis AG
- Pfizer, Inc.
- Sanofi Pasteur SA
- Sinovac Biotech Ltd.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca Plc
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. Hoffmann-La Roche Ltd
- Gamma Vaccines Pty Ltd
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter'S Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High Prevalence of Influenza
3.4.1.2. Increase In Government Focus On Immunization Programs
3.4.1.3. Emerging Vaccines
3.4.1.4. Technological Progress In Vaccine Administration
3.4.2. Restraints
3.4.2.1. Longer Timelines And Implementation of Stringent Regulations
3.4.2.2. High Costs Associated With The Development of Vaccines
3.4.3. Opportunity
3.4.3.1. High Growth Prospects In Emerging Markets
Chapter 4: Influenza Vaccine Market, By Vaccine Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Quadrivalent
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Trivalent
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
Chapter 5: Influenza Vaccine Market, By Type
5.1. Overview
5.2. Seasonal Influenza Vaccine
5.3. Pandemic Influenza Vaccine
Chapter 6: Influenza Vaccine Market, By Technology
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Egg-Based
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Cell Culture
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
Chapter 7: Influenza Vaccine Market, By Age Group
7.1. Overview
7.1.1. Market Size And Forecast
7.2. Pediatric
7.2.1. Market Size And Forecast, By Region
7.2.2. Market Analysis, By Country
7.3. Adult
7.3.1. Market Size And Forecast, By Region
7.3.2. Market Analysis, By Country
Chapter 8: Influenza Vaccine Market, By Route of Administration
8.1. Overview
8.1.1. Market Size And Forecast
8.2. Injection
8.2.1. Market Size And Forecast
8.2.2. Market Analysis, By Country
8.3. Nasal Spray
8.3.1. Market Size And Forecast
8.3.2. Market Analysis, By Country
Chapter 9: Global Influenza Vaccine Market, By Region
9.1. Overview
9.1.1. Market Size And Forecast
9.2. North America
9.2.1. Key Market Trends And Opportunities
9.2.2. Market Size And Forecast, By Vaccine Type
9.2.3. Market Size And Forecast, By Technology
9.2.4. Market Size And Forecast, By Age Group
9.2.5. Market Size And Forecast, By Route of Administration
9.2.6. Market Size And Forecast, By Country
9.2.6.1. U.S. Market Size And Forecast, By Vaccine Type
9.2.6.2. U.S. Market Size And Forecast, By Technology
9.2.6.3. U.S. Market Size And Forecast, By Age Group
9.2.6.4. U.S. Market Size And Forecast, By Route of Administration
9.2.6.5. Canada Market Size And Forecast, By Vaccine Type
9.2.6.6. Canada Market Size And Forecast, By Technology
9.2.6.7. Canada Market Size And Forecast, By Age Group
9.2.6.8. Canada Market Size And Forecast, By Route of Administration
9.2.6.9. Mexico Market Size And Forecast, By Vaccine Type
9.2.6.10. Mexico Market Size And Forecast, By Technology
9.2.6.11. Mexico Market Size And Forecast, By Age Group
9.2.6.12. Mexico Market Size And Forecast, By Route of Administration
9.3. Europe
9.3.1. Key Market Trends And Opportunities
9.3.2. Market Size And Forecast, By Vaccine Type
9.3.3. Market Size And Forecast, By Technology
9.3.4. Market Size And Forecast, By Age Group
9.3.5. Market Size And Forecast, By Route of Administration
9.3.6. Market Size And Forecast, By Country
9.3.6.1. Germany Market Size And Forecast, By Vaccine Type
9.3.6.2. Germany Market Size And Forecast, By Technology
9.3.6.3. Germany Market Size And Forecast, By Age Group
9.3.6.4. Germany Market Size And Forecast, By Route of Administration
9.3.6.5. France Market Size And Forecast, By Vaccine Type
9.3.6.6. France Market Size And Forecast, By Technology
9.3.6.7. France Market Size And Forecast, By Age Group
9.3.6.8. France Market Size And Forecast, By Route of Administration
9.3.6.9. UK Market Size And Forecast, By Vaccine Type
9.3.6.10. UK Market Size And Forecast, By Technology
9.3.6.11. UK Market Size And Forecast, By Age Group
9.3.6.12. UK Market Size And Forecast, By Route of Administration
9.3.6.13. Italy Market Size And Forecast, By Vaccine Type
9.3.6.14. Italy Market Size And Forecast, By Technology
9.3.6.15. Italy Market Size And Forecast, By Age Group
9.3.6.16. Italy Market Size And Forecast, By Route of Administration
9.3.6.17. Spain Market Size And Forecast, By Vaccine Type
9.3.6.18. Spain Market Size And Forecast, By Technology
9.3.6.19. Spain Market Size And Forecast, By Age Group
9.3.6.20. Spain Market Size And Forecast, By Route of Administration
9.3.6.21. Rest of Europe Market Size And Forecast, By Vaccine Type
9.3.6.22. Rest of Europe Market Size And Forecast, By Technology
9.3.6.23. Rest of Europe Market Size And Forecast, By Age Group
9.3.6.24. Rest of Europe Market Size And Forecast, By Route of Administration
9.4. Asia-Pacific
9.4.1. Key Market Trends And Opportunities
9.4.2. Market Size And Forecast, By Vaccine Type
9.4.3. Market Size And Forecast, By Technology
9.4.4. Market Size And Forecast, By Age Group
9.4.5. Market Size And Forecast, By Route of Administration
9.4.6. Market Size And Forecast, By Country
9.4.6.1. Japan Market Size And Forecast, By Vaccine Type
9.4.6.2. Japan Market Size And Forecast, By Technology
9.4.6.3. Japan Market Size And Forecast, By Age Group
9.4.6.4. Japan Market Size And Forecast, By Route of Administration
9.4.6.5. China Market Size And Forecast, By Vaccine Type
9.4.6.6. China Market Size And Forecast, By Technology
9.4.6.7. China Market Size And Forecast, By Age Group
9.4.6.8. China Market Size And Forecast, By Route of Administration
9.4.6.9. India Market Size And Forecast, By Vaccine Type
9.4.6.10. India Market Size And Forecast, By Technology
9.4.6.11. India Market Size And Forecast, By Age Group
9.4.6.12. India Market Size And Forecast, By Route of Administration
9.4.6.13. Australia Market Size And Forecast, By Vaccine Type
9.4.6.14. Australia Market Size And Forecast, By Technology
9.4.6.15. Australia Market Size And Forecast, By Age Group
9.4.6.16. Australia Market Size And Forecast, By Route of Administration
9.4.6.17. South Korea Market Size And Forecast, By Vaccine Type
9.4.6.18. South Korea Market Size And Forecast, By Technology
9.4.6.19. South Korea Market Size And Forecast, By Age Group
9.4.6.20. South Korea Market Size And Forecast, By Route of Administration
9.4.6.21. Rest of Asia-Pacific Market Size And Forecast, By Vaccine Type
9.4.6.22. Rest of Asia-Pacific Market Size And Forecast, By Technology
9.4.6.23. Rest of Asia-Pacific Market Size And Forecast, By Age Group
9.4.6.24. Rest of Asia-Pacific Market Size And Forecast, By Route of Administration
9.5. LAMEA
9.5.1. Key Market Trends And Opportunities
9.5.2. Market Size And Forecast, By Vaccine Type
9.5.3. Market Size And Forecast, By Technology
9.5.4. Market Size And Forecast, By Age Group
9.5.5. Market Size And Forecast, By Route of Administration
9.5.6. Market Size And Forecast, By Country
9.5.6.1. Brazil Market Size And Forecast, By Vaccine Type
9.5.6.2. Brazil Market Size And Forecast, By Technology
9.5.6.3. Brazil Market Size And Forecast, By Age Group
9.5.6.4. Brazil Market Size And Forecast, By Route of Administration
9.5.6.5. Saudi Market Size And Forecast, By Vaccine Type
9.5.6.6. Saudi Market Size And Forecast, By Technology
9.5.6.7. Saudi Market Size And Forecast, By Age Group
9.5.6.8. Saudi Market Size And Forecast, By Route of Administration
9.5.6.9. South Africa Market Size And Forecast, By Vaccine Type
9.5.6.10. South Africa Market Size And Forecast, By Technology
9.5.6.11. South Africa Market Size And Forecast, By Age Group
9.5.6.12. South Africa Market Size And Forecast, By Route of Administration
9.5.6.13. Rest of LAMEA Market Size And Forecast, By Vaccine Type
9.5.6.14. Rest of LAMEA Market Size And Forecast, By Technology
9.5.6.15. Rest of LAMEA Market Size And Forecast, By Age Group
9.5.6.16. Rest of LAMEA Market Size And Forecast, By Route of Administration
Chapter 10: Company Profiles
10.1. Astrazeneca Plc (Astrazeneca)
10.1.1. Company Overview
10.1.2. Company Snapshot
10.1.3. Operating Business Segments
10.1.4. Product Portfolio
10.1.5. Business Performance
10.2. Biodiem
10.2.1. Company Overview
10.2.2. Company Snapshot
10.2.3. Operating Business Segments
10.2.4. Product Portfolio
10.2.5. Business Performance
10.3. Csl Limited (Seqirus Gmbh)
10.3.1. Company Overview
10.3.2. Company Snapshot
10.3.3. Operating Business Segments
10.3.4. Product Portfolio
10.3.5. Business Performance
10.3.6. Key Strategic Moves And Developments
10.4. Emergent Biosolutions
10.4.1. Company Overview
10.4.2. Company Snapshot
10.4.3. Operating Business Segments
10.4.4. Product Portfolio
10.4.5. Business Performance
10.5. F. Hoffmann-La Roche Ltd.
10.5.1. Company Overview
10.5.2. Company Snapshot
10.5.3. Operating Business Segments
10.5.4. Product Portfolio
10.5.5. Business Performance
10.6. Gamma Vaccines Pty Ltd.
10.6.1. Company Overview
10.6.2. Company Snapshot
10.6.3. Operating Business Segments
10.6.4. Product Portfolio
10.7. Glaxosmithkline Plc
10.7.1. Company Overview
10.7.2. Company Snapshot
10.7.3. Operating Business Segments
10.7.4. Product Portfolio
10.7.5. Business Performance
10.7.6. Key Strategic Moves And Developments
10.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
10.8.1. Company Overview
10.8.2. Company Snapshot
10.8.3. Operating Business Segments
10.8.4. Product Portfolio
10.8.5. Business Performance
10.9. Novartis Ag
10.9.1. Company Overview
10.9.2. Company Snapshot
10.9.3. Operating Business Segments
10.9.4. Product Portfolio
10.9.5. Business Performance
10.10. Pfizer, Inc.
10.10.1. Company Overview
10.10.2. Company Snapshot
10.10.3. Operating Business Segments
10.10.4. Product Portfolio
10.10.5. Business Performance
10.10.6. Key Strategic Moves And Developments
10.11. Sanofi
10.11.1. Company Overview
10.11.2. Company Snapshot
10.11.3. Operating Business Segments
10.11.4. Product Portfolio
10.11.5. Business Performance
10.12. Sinovac Biotech Ltd.
10.12.1. Company Overview
10.12.2. Company Snapshot
10.12.3. Operating Business Segments
10.12.4. Product Portfolio
10.12.5. Business Performance
*Full List of Tables and Figures Available on Enquiry.
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter'S Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High Prevalence of Influenza
3.4.1.2. Increase In Government Focus On Immunization Programs
3.4.1.3. Emerging Vaccines
3.4.1.4. Technological Progress In Vaccine Administration
3.4.2. Restraints
3.4.2.1. Longer Timelines And Implementation of Stringent Regulations
3.4.2.2. High Costs Associated With The Development of Vaccines
3.4.3. Opportunity
3.4.3.1. High Growth Prospects In Emerging Markets
Chapter 4: Influenza Vaccine Market, By Vaccine Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Quadrivalent
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Trivalent
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
Chapter 5: Influenza Vaccine Market, By Type
5.1. Overview
5.2. Seasonal Influenza Vaccine
5.3. Pandemic Influenza Vaccine
Chapter 6: Influenza Vaccine Market, By Technology
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Egg-Based
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Cell Culture
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
Chapter 7: Influenza Vaccine Market, By Age Group
7.1. Overview
7.1.1. Market Size And Forecast
7.2. Pediatric
7.2.1. Market Size And Forecast, By Region
7.2.2. Market Analysis, By Country
7.3. Adult
7.3.1. Market Size And Forecast, By Region
7.3.2. Market Analysis, By Country
Chapter 8: Influenza Vaccine Market, By Route of Administration
8.1. Overview
8.1.1. Market Size And Forecast
8.2. Injection
8.2.1. Market Size And Forecast
8.2.2. Market Analysis, By Country
8.3. Nasal Spray
8.3.1. Market Size And Forecast
8.3.2. Market Analysis, By Country
Chapter 9: Global Influenza Vaccine Market, By Region
9.1. Overview
9.1.1. Market Size And Forecast
9.2. North America
9.2.1. Key Market Trends And Opportunities
9.2.2. Market Size And Forecast, By Vaccine Type
9.2.3. Market Size And Forecast, By Technology
9.2.4. Market Size And Forecast, By Age Group
9.2.5. Market Size And Forecast, By Route of Administration
9.2.6. Market Size And Forecast, By Country
9.2.6.1. U.S. Market Size And Forecast, By Vaccine Type
9.2.6.2. U.S. Market Size And Forecast, By Technology
9.2.6.3. U.S. Market Size And Forecast, By Age Group
9.2.6.4. U.S. Market Size And Forecast, By Route of Administration
9.2.6.5. Canada Market Size And Forecast, By Vaccine Type
9.2.6.6. Canada Market Size And Forecast, By Technology
9.2.6.7. Canada Market Size And Forecast, By Age Group
9.2.6.8. Canada Market Size And Forecast, By Route of Administration
9.2.6.9. Mexico Market Size And Forecast, By Vaccine Type
9.2.6.10. Mexico Market Size And Forecast, By Technology
9.2.6.11. Mexico Market Size And Forecast, By Age Group
9.2.6.12. Mexico Market Size And Forecast, By Route of Administration
9.3. Europe
9.3.1. Key Market Trends And Opportunities
9.3.2. Market Size And Forecast, By Vaccine Type
9.3.3. Market Size And Forecast, By Technology
9.3.4. Market Size And Forecast, By Age Group
9.3.5. Market Size And Forecast, By Route of Administration
9.3.6. Market Size And Forecast, By Country
9.3.6.1. Germany Market Size And Forecast, By Vaccine Type
9.3.6.2. Germany Market Size And Forecast, By Technology
9.3.6.3. Germany Market Size And Forecast, By Age Group
9.3.6.4. Germany Market Size And Forecast, By Route of Administration
9.3.6.5. France Market Size And Forecast, By Vaccine Type
9.3.6.6. France Market Size And Forecast, By Technology
9.3.6.7. France Market Size And Forecast, By Age Group
9.3.6.8. France Market Size And Forecast, By Route of Administration
9.3.6.9. UK Market Size And Forecast, By Vaccine Type
9.3.6.10. UK Market Size And Forecast, By Technology
9.3.6.11. UK Market Size And Forecast, By Age Group
9.3.6.12. UK Market Size And Forecast, By Route of Administration
9.3.6.13. Italy Market Size And Forecast, By Vaccine Type
9.3.6.14. Italy Market Size And Forecast, By Technology
9.3.6.15. Italy Market Size And Forecast, By Age Group
9.3.6.16. Italy Market Size And Forecast, By Route of Administration
9.3.6.17. Spain Market Size And Forecast, By Vaccine Type
9.3.6.18. Spain Market Size And Forecast, By Technology
9.3.6.19. Spain Market Size And Forecast, By Age Group
9.3.6.20. Spain Market Size And Forecast, By Route of Administration
9.3.6.21. Rest of Europe Market Size And Forecast, By Vaccine Type
9.3.6.22. Rest of Europe Market Size And Forecast, By Technology
9.3.6.23. Rest of Europe Market Size And Forecast, By Age Group
9.3.6.24. Rest of Europe Market Size And Forecast, By Route of Administration
9.4. Asia-Pacific
9.4.1. Key Market Trends And Opportunities
9.4.2. Market Size And Forecast, By Vaccine Type
9.4.3. Market Size And Forecast, By Technology
9.4.4. Market Size And Forecast, By Age Group
9.4.5. Market Size And Forecast, By Route of Administration
9.4.6. Market Size And Forecast, By Country
9.4.6.1. Japan Market Size And Forecast, By Vaccine Type
9.4.6.2. Japan Market Size And Forecast, By Technology
9.4.6.3. Japan Market Size And Forecast, By Age Group
9.4.6.4. Japan Market Size And Forecast, By Route of Administration
9.4.6.5. China Market Size And Forecast, By Vaccine Type
9.4.6.6. China Market Size And Forecast, By Technology
9.4.6.7. China Market Size And Forecast, By Age Group
9.4.6.8. China Market Size And Forecast, By Route of Administration
9.4.6.9. India Market Size And Forecast, By Vaccine Type
9.4.6.10. India Market Size And Forecast, By Technology
9.4.6.11. India Market Size And Forecast, By Age Group
9.4.6.12. India Market Size And Forecast, By Route of Administration
9.4.6.13. Australia Market Size And Forecast, By Vaccine Type
9.4.6.14. Australia Market Size And Forecast, By Technology
9.4.6.15. Australia Market Size And Forecast, By Age Group
9.4.6.16. Australia Market Size And Forecast, By Route of Administration
9.4.6.17. South Korea Market Size And Forecast, By Vaccine Type
9.4.6.18. South Korea Market Size And Forecast, By Technology
9.4.6.19. South Korea Market Size And Forecast, By Age Group
9.4.6.20. South Korea Market Size And Forecast, By Route of Administration
9.4.6.21. Rest of Asia-Pacific Market Size And Forecast, By Vaccine Type
9.4.6.22. Rest of Asia-Pacific Market Size And Forecast, By Technology
9.4.6.23. Rest of Asia-Pacific Market Size And Forecast, By Age Group
9.4.6.24. Rest of Asia-Pacific Market Size And Forecast, By Route of Administration
9.5. LAMEA
9.5.1. Key Market Trends And Opportunities
9.5.2. Market Size And Forecast, By Vaccine Type
9.5.3. Market Size And Forecast, By Technology
9.5.4. Market Size And Forecast, By Age Group
9.5.5. Market Size And Forecast, By Route of Administration
9.5.6. Market Size And Forecast, By Country
9.5.6.1. Brazil Market Size And Forecast, By Vaccine Type
9.5.6.2. Brazil Market Size And Forecast, By Technology
9.5.6.3. Brazil Market Size And Forecast, By Age Group
9.5.6.4. Brazil Market Size And Forecast, By Route of Administration
9.5.6.5. Saudi Market Size And Forecast, By Vaccine Type
9.5.6.6. Saudi Market Size And Forecast, By Technology
9.5.6.7. Saudi Market Size And Forecast, By Age Group
9.5.6.8. Saudi Market Size And Forecast, By Route of Administration
9.5.6.9. South Africa Market Size And Forecast, By Vaccine Type
9.5.6.10. South Africa Market Size And Forecast, By Technology
9.5.6.11. South Africa Market Size And Forecast, By Age Group
9.5.6.12. South Africa Market Size And Forecast, By Route of Administration
9.5.6.13. Rest of LAMEA Market Size And Forecast, By Vaccine Type
9.5.6.14. Rest of LAMEA Market Size And Forecast, By Technology
9.5.6.15. Rest of LAMEA Market Size And Forecast, By Age Group
9.5.6.16. Rest of LAMEA Market Size And Forecast, By Route of Administration
Chapter 10: Company Profiles
10.1. Astrazeneca Plc (Astrazeneca)
10.1.1. Company Overview
10.1.2. Company Snapshot
10.1.3. Operating Business Segments
10.1.4. Product Portfolio
10.1.5. Business Performance
10.2. Biodiem
10.2.1. Company Overview
10.2.2. Company Snapshot
10.2.3. Operating Business Segments
10.2.4. Product Portfolio
10.2.5. Business Performance
10.3. Csl Limited (Seqirus Gmbh)
10.3.1. Company Overview
10.3.2. Company Snapshot
10.3.3. Operating Business Segments
10.3.4. Product Portfolio
10.3.5. Business Performance
10.3.6. Key Strategic Moves And Developments
10.4. Emergent Biosolutions
10.4.1. Company Overview
10.4.2. Company Snapshot
10.4.3. Operating Business Segments
10.4.4. Product Portfolio
10.4.5. Business Performance
10.5. F. Hoffmann-La Roche Ltd.
10.5.1. Company Overview
10.5.2. Company Snapshot
10.5.3. Operating Business Segments
10.5.4. Product Portfolio
10.5.5. Business Performance
10.6. Gamma Vaccines Pty Ltd.
10.6.1. Company Overview
10.6.2. Company Snapshot
10.6.3. Operating Business Segments
10.6.4. Product Portfolio
10.7. Glaxosmithkline Plc
10.7.1. Company Overview
10.7.2. Company Snapshot
10.7.3. Operating Business Segments
10.7.4. Product Portfolio
10.7.5. Business Performance
10.7.6. Key Strategic Moves And Developments
10.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
10.8.1. Company Overview
10.8.2. Company Snapshot
10.8.3. Operating Business Segments
10.8.4. Product Portfolio
10.8.5. Business Performance
10.9. Novartis Ag
10.9.1. Company Overview
10.9.2. Company Snapshot
10.9.3. Operating Business Segments
10.9.4. Product Portfolio
10.9.5. Business Performance
10.10. Pfizer, Inc.
10.10.1. Company Overview
10.10.2. Company Snapshot
10.10.3. Operating Business Segments
10.10.4. Product Portfolio
10.10.5. Business Performance
10.10.6. Key Strategic Moves And Developments
10.11. Sanofi
10.11.1. Company Overview
10.11.2. Company Snapshot
10.11.3. Operating Business Segments
10.11.4. Product Portfolio
10.11.5. Business Performance
10.12. Sinovac Biotech Ltd.
10.12.1. Company Overview
10.12.2. Company Snapshot
10.12.3. Operating Business Segments
10.12.4. Product Portfolio
10.12.5. Business Performance
*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca Plc
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. Hoffmann-La Roche Ltd
- Gamma Vaccines Pty Ltd
According to the report titled, ' Influenza Vaccine Market by Vaccine Type, Technology, Age Group, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global influenza vaccine market size was $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026. The quadrivalent segment accounted more than three-fifth of the total influenza vaccine market share in 2018.
Influenza is an acute respiratory infection caused by influenza viruses leading to illness that affects humans and animals. These viruses are genetically dynamic and evolve unpredictively each year on seasonal basis. Thus, seasonal influenza epidemics are caused by newer strains that are antigenically different from the previous circulating strain. The changes in the genetics of the influenza virus strains further results in the development of new vaccines yearly.
The influenza vaccine market growth is strongly driven by government initiatives worldwide, minimal risk of side effects associated with influenza vaccines, increase in efficacy levels of the vaccines, and advancements in development of newer influenza vaccines. Furthermore, increased funding from major companies for R&D activities for development of influenza vaccines in developed countries such as the U.S. and Canada further boosts the demand for influenza vaccines globally. However, higher costs associated with the development of vaccines and prolonged time span their production are expected to hinder the market growth.
By vaccine type, the global influenza vaccine market is divided into quadrivalent and trivalent. The quadrivalent segment was the major revenue contributor in 2018, owing to its ability to immunize four influenza virus strains (two A subtypes and two B subtypes - H1N1 and H3N2 and Victoria and Yamagata, respectively).
By age group, it is bifurcated into pediatric and adult. The adult age group segment was the highest contributor in the market in 2018 and is expected to remain dominant during the forecast period, owing to higher risks of developing serious complications from influenza due to weak immune response.
North America is the highest revenue contributor in the global influenza vaccine market and accounted for more than 40% share in 2018. On the other hand, LAMEA is expected to grow at a CAGR of 7.5%, owing to rise in incidences of influenza among children and increase in private healthcare expenditure.
The report provides a comprehensive analysis of the key players operating in the global AstraZeneca Plc, Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd.
Key Findings of the Influenza Vaccine Market:
Based on technology, the egg-based segment was the major revenue contributor in 2018 and is anticipated to continue this trend during the forecast period.
Based on age group, its pediatric segment is expected to exhibit the highest CAGR with 6.1% during the forecast period.
Depending on route of administration, the injection segment was the largest revenue contributor in 2018 and is expected to continue this trend from 2019 to 2026.
U.S. generated the highest revenue in the global influenza vaccine market in 2018, accounting for more than two-fifth of the global market in 2018.
LAMEA is estimated to grow at the highest CAGR during the forecast period.
Influenza is an acute respiratory infection caused by influenza viruses leading to illness that affects humans and animals. These viruses are genetically dynamic and evolve unpredictively each year on seasonal basis. Thus, seasonal influenza epidemics are caused by newer strains that are antigenically different from the previous circulating strain. The changes in the genetics of the influenza virus strains further results in the development of new vaccines yearly.
The influenza vaccine market growth is strongly driven by government initiatives worldwide, minimal risk of side effects associated with influenza vaccines, increase in efficacy levels of the vaccines, and advancements in development of newer influenza vaccines. Furthermore, increased funding from major companies for R&D activities for development of influenza vaccines in developed countries such as the U.S. and Canada further boosts the demand for influenza vaccines globally. However, higher costs associated with the development of vaccines and prolonged time span their production are expected to hinder the market growth.
By vaccine type, the global influenza vaccine market is divided into quadrivalent and trivalent. The quadrivalent segment was the major revenue contributor in 2018, owing to its ability to immunize four influenza virus strains (two A subtypes and two B subtypes - H1N1 and H3N2 and Victoria and Yamagata, respectively).
By age group, it is bifurcated into pediatric and adult. The adult age group segment was the highest contributor in the market in 2018 and is expected to remain dominant during the forecast period, owing to higher risks of developing serious complications from influenza due to weak immune response.
North America is the highest revenue contributor in the global influenza vaccine market and accounted for more than 40% share in 2018. On the other hand, LAMEA is expected to grow at a CAGR of 7.5%, owing to rise in incidences of influenza among children and increase in private healthcare expenditure.
The report provides a comprehensive analysis of the key players operating in the global AstraZeneca Plc, Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd.
Key Findings of the Influenza Vaccine Market:
Based on technology, the egg-based segment was the major revenue contributor in 2018 and is anticipated to continue this trend during the forecast period.
Based on age group, its pediatric segment is expected to exhibit the highest CAGR with 6.1% during the forecast period.
Depending on route of administration, the injection segment was the largest revenue contributor in 2018 and is expected to continue this trend from 2019 to 2026.
U.S. generated the highest revenue in the global influenza vaccine market in 2018, accounting for more than two-fifth of the global market in 2018.
LAMEA is estimated to grow at the highest CAGR during the forecast period.
Note: Product cover images may vary from those shown
- AstraZeneca Plc
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. Hoffmann-La Roche Ltd
- Gamma Vaccines Pty Ltd
- GlaxoSmithKline plc
- Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
- Novartis AG
- Pfizer Inc.
- Sanofi Pasteur SA
- Sinovac
Note: Product cover images may vary from those shown
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
